Major Indian Generics Go For Ensured Revenue Rather Than U.S. Patent Courts (India)
This article was originally published in PharmAsia News
Major Indian Generics Go For Ensured Revenue Rather Than U.S. Patent Courts (India) Major Indian pharmaceutical companies tend to accept out-of-court settlements of patent suits because they realize they need a continuous revenue flow from business abroad. Ranbaxy Laboratories, Dr. Reddy's, Lupin, Ranbaxy, Sun Pharma and Wockhardt have reached settlements by suing U.S. drug makers where in the past they might have pressed their claims in court. Each of the settled cases has involved a deal to be announced later guaranteeing a continued flow of income through the U.S. maker. Industry experts say those agreements are a sign generics makers are becoming more mature. (Click here for more )
You may also be interested in...
Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.